This titration approach is consistent with other incretin-based therapies and is designed to minimise gastrointestinal side effects during the initiation period
Ficlatuzumab has been demonstrated to interfere with stromal contributions to proliferation, migration, and invasion in a preclinical in vitro model of HNSCC, as well as epithelial to mesenchymal transition (EMT) [118]
For controlled skin studies, topical application removes the confounders introduced by injection no injection site reactions, no systemic distribution diluting local concentration, no injection technique variability across research subjects
My name got passed around, he told me
Arcidiacono B, Chiefari E, Foryst-Ludwig A, et al
The injection